EASL 2026 Reflections: Key takeaways in late-onset genetic cholestasis and Alagille syndrome
Dr Silvia Vilarinho and Dr Deepak Joshi reflect on the highlights from EASL Congress 2026, focusing on late‑onset genetic cholestasis and new insights in Alagille syndrome. They discuss the expanding role of genomic testing in adults, the move toward multidisciplinary Genetic Grand Rounds, and emerging IBAT‑targeted therapies and pregnancy data that are changing diagnosis and management.
Evolving therapeutic approaches in late-onset genetic cholestasis
Carola Dröge and Verena Keitel-Anselmino discuss IBAT inhibitor therapy in adults with hereditary BSEP-deficiency at EASL 2026.
Observational data show IBAT inhibitor promise for pruritus in late-onset PFIC and ICP
Real-world data show promise for IBAT inhibitor use in adults with late-onset PFIC and women with ICP.
Uncovering hidden genetic causes in adult cholestasis
Jeremy Nayagam highlights research on genetic testing in adults with unexplained cholestatic liver disease and hepatitis and explains why such testing is important in the diagnosis of these patients.
Case series suggests IBAT inhibitor benefits in adults with hereditary BSEP deficiency
Clinical data suggest comparable IBAT inhibitor response for adults with hereditary BSEP deficiency as seen in pediatric trials.
Targeted gene sequencing panel resolves unexplained cholestasis in about 5% of adults
A targeted next generation sequencing gene panel could offer a definitive diagnosis for some adults with unexplained cholestasis.
Genetic variants explain substantial proportion of undiagnosed cholestasis and hepatitis
Study findings support early genetic testing for unexplained idiopathic chronic cholestasis and hepatitis of unknown origin.
AASLD 2025 Reflections: Key takeaways in late-onset genetic cholestasis
Dr Silvia Vilarinho and Dr Deepak Joshi share the highlights from AASLD The Liver Meeting 2025, with an emphasis on late-onset genetic cholestasis, and offer quick insights into new data on the growing utility of genetic testing and expanding therapeutic implications.
Genetic etiology may explain majority of adult-onset cholestatic disorders
Most cases of unexplained cholestasis in adults have an identifiable underlying genetic cause.
Next generation sequencing may offer diagnoses in adult unexplained cholestasis
Adults living with unexplained cholestasis could receive a diagnosis with next generation sequencing, suggests US study.
Novel panel identifies variants in unexplained cholestatic cases
A large US gene panel has helped to elucidate the underlying genetic basis of unexplained cholestasis.
Gene mutations linked to adult cholestasis
Mitchell Shiffman discusses the value of genetic testing in adults with undefined cholestasis.
NLP medical review may help identify adults with undiagnosed PFIC
Natural language programming could help identify which adults with cholestasis have late-onset progressive familial intrahepatic cholestasis.
IBAT inhibitors may improve post-liver transplant pruritus
Treatment-refractory pruritus following liver transplant may be successfully treated with IBAT inhibitors, suggests a US case series.
